NO763773L - - Google Patents

Info

Publication number: NO763773L
Authority: NO; Norway
Prior art keywords: double; stated; ribonucleic acid; complex; stranded
Prior art date: 1975-11-07

Application number

NO763773A

Other languages

English (en)

Norwegian (no)

Inventor

J W G Leiper

Original Assignee

Beecham Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-11-07

Filing date

1976-11-05

Publication date

1977-05-10

1976-11-05 Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd

1977-05-10 Publication of NO763773L publication Critical patent/NO763773L/no

Links

238000000034 method Methods 0.000 claims description 29
241000283690 Bos taurus Species 0.000 claims description 24
229920002477 rna polymer Polymers 0.000 claims description 23
238000011282 treatment Methods 0.000 claims description 23
238000002360 preparation method Methods 0.000 claims description 20
208000004396 mastitis Diseases 0.000 claims description 19
230000003115 biocidal effect Effects 0.000 claims description 18
210000005075 mammary gland Anatomy 0.000 claims description 17
210000000481 breast Anatomy 0.000 claims description 15
229930182555 Penicillin Natural products 0.000 claims description 9
LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 8
229960003326 cloxacillin Drugs 0.000 claims description 8
229930186147 Cephalosporin Natural products 0.000 claims description 7
241000228150 Penicillium chrysogenum Species 0.000 claims description 7
229940124587 cephalosporin Drugs 0.000 claims description 7
150000001780 cephalosporins Chemical class 0.000 claims description 7
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
230000001580 bacterial effect Effects 0.000 claims description 6
OCLRGULJISNUQS-OXQOHEQNSA-N (6r,7r)-3-(acetyloxymethyl)-7-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl OCLRGULJISNUQS-OXQOHEQNSA-N 0.000 claims description 5
229950002823 cefoxazole Drugs 0.000 claims description 5
229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 5
108010011110 polyarginine Proteins 0.000 claims description 5
229940049954 penicillin Drugs 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 description 22
210000002445 nipple Anatomy 0.000 description 20
235000013336 milk Nutrition 0.000 description 17
239000008267 milk Substances 0.000 description 17
210000004080 milk Anatomy 0.000 description 17
210000004027 cell Anatomy 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
238000001802 infusion Methods 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 8
229940088710 antibiotic agent Drugs 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000008187 granular material Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
150000002960 penicillins Chemical class 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
230000002949 hemolytic effect Effects 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
230000006651 lactation Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
239000002674 ointment Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229960003022 amoxicillin Drugs 0.000 description 3
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
229940093905 ampicillin / cloxacillin Drugs 0.000 description 3
235000013365 dairy product Nutrition 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108010065152 Coagulase Proteins 0.000 description 2
UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000282520 Papio Species 0.000 description 2
241000191940 Staphylococcus Species 0.000 description 2
241000194054 Streptococcus uberis Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000011149 active material Substances 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
-1 cloxacillin Chemical compound 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000008260 defense mechanism Effects 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
229960004273 floxacillin Drugs 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
FHNKBSDJERHDHZ-UHFFFAOYSA-N (2,4-dimethylphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=C(C)C=C1C FHNKBSDJERHDHZ-UHFFFAOYSA-N 0.000 description 1
FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
241000892910 Aspergillus foetidus Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241000120529 Chenuda virus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
244000182625 Dictamnus albus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
241000228145 Penicillium brevicompactum Species 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229960003669 carbenicillin Drugs 0.000 description 1
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
229960002543 carfecillin Drugs 0.000 description 1
NZDASSHFKWDBBU-KVMCETHSSA-N carfecillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C=1C=CC=CC=1)C(=O)OC1=CC=CC=C1 NZDASSHFKWDBBU-KVMCETHSSA-N 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 description 1
229960003026 cloxacillin sodium Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960001585 dicloxacillin Drugs 0.000 description 1
YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
244000144980 herd Species 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
239000012170 montan wax Substances 0.000 description 1
229960000515 nafcillin Drugs 0.000 description 1
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960001019 oxacillin Drugs 0.000 description 1
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
244000052769 pathogen Species 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940115922 streptococcus uberis Drugs 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229960002780 talampicillin Drugs 0.000 description 1
SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229960004659 ticarcillin Drugs 0.000 description 1
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Pregnancy & Childbirth (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO763773A 1975-11-07 1976-11-05 NO763773L (xx)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB4615375		1975-11-07

Publications (1)

Publication Number	Publication Date
NO763773L true NO763773L (xx)	1977-05-10

Family

ID=10440078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO763773A NO763773L (xx)	1975-11-07	1976-11-05

Country Status (10)

Country	Link
JP (1)	JPS5261234A (xx)
AU (1)	AU1941576A (xx)
BE (1)	BE847990A (xx)
DE (1)	DE2650608A1 (xx)
DK (1)	DK501076A (xx)
FR (1)	FR2361102A1 (xx)
NL (1)	NL7612352A (xx)
NO (1)	NO763773L (xx)
SE (1)	SE7612343L (xx)
ZA (1)	ZA766645B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1981001102A1 (en) *	1979-10-19	1981-04-30	A Romano	Medicine for the treatment of viral infections of the eye and other organs
AU2018333274A1 (en) *	2017-09-12	2020-04-23	Mammbio Pty Ltd	Methods for reducing or shutting down lactation in non-human mammals and reagents therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1170929A (en) *	1965-12-28	1969-11-19	Glaxo Lab Ltd	Antirival Nucleic Acids.
US3636194A (en) *	1969-10-23	1972-01-18	Douglas G Parizeau	Composition and method for treating mastitis with therapeutic agents

1976
- 1976-11-04 SE SE7612343A patent/SE7612343L/xx unknown
- 1976-11-04 BE BE172085A patent/BE847990A/xx unknown
- 1976-11-04 DE DE19762650608 patent/DE2650608A1/de active Pending
- 1976-11-05 FR FR7633410A patent/FR2361102A1/fr not_active Withdrawn
- 1976-11-05 NO NO763773A patent/NO763773L/no unknown
- 1976-11-05 DK DK501076A patent/DK501076A/da unknown
- 1976-11-05 ZA ZA766645A patent/ZA766645B/xx unknown
- 1976-11-05 NL NL7612352A patent/NL7612352A/xx not_active Application Discontinuation
- 1976-11-06 JP JP51133669A patent/JPS5261234A/ja active Pending
- 1976-11-08 AU AU19415/76A patent/AU1941576A/en not_active Expired

Also Published As

Publication number	Publication date
BE847990A (fr)	1977-05-04
NL7612352A (nl)	1977-05-10
DE2650608A1 (de)	1977-05-18
ZA766645B (en)	1977-10-26
JPS5261234A (en)	1977-05-20
AU1941576A (en)	1978-05-18
FR2361102A1 (fr)	1978-03-10
SE7612343L (sv)	1977-05-08
DK501076A (da)	1977-05-08

Publication	Publication Date	Title
Alexander	2010	Infectious bovine keratoconjunctivitis: a review of cases in clinical practice
KR19990022220A (ko)	1999-03-25	의료 용도의 미소-캡슐화된 락토바실러스
US5484609A (en)	1996-01-16	Therapeutic compositions and methods
EP2120860A2 (en)	2009-11-25	Pharmaceutical compositions and method for treating inflammation in cattle and other animals
AU672384B2 (en)	1996-10-03	Pharmaceutical bacteriocin compositions
US4749568A (en)	1988-06-07	Rubradirin treatment of methicillin-resistant staph
US2607716A (en)	1952-08-19	Prophylactic compositon for scours
RU2197237C2 (ru)	2003-01-27	Способ лечения заболеваний животных, вызванных бактериями (варианты), и способ изготовления лекарственного средства
US6132715A (en)	2000-10-17	Method of inhibiting biosynthesis of tumor necrosis factor
Bare et al.	1964	Effects of dietary antibiotics and uric acid on the growth of chicks
NO763773L (xx)	1977-05-10
US20030039703A1 (en)	2003-02-27	Use of chlorate ion or preparations thereof for reduction of food borne pathogens
US4610993A (en)	1986-09-09	Use of selected pyridine-N-oxide disulfide compounds to treat or prevent bovine mastitis
Watson et al.	1986	Effect of ingesta on systemic availability of penicillins administered orally in dogs
Ziv et al.	1973	Retention of Antibiotics in Dry‐Udder Secretions after the Infusion of Several “Dry Cow” Antibiotic Products
JP2001518052A (ja)	2001-10-09	長期治療のための獣医用経口フルオロキノロン抗菌組成物及び治療方法
CA1285226C (en)	1991-06-25	Compositions containing a 2,4-diamino-pyrimidine and sulphadimidine
RU2103997C1 (ru)	1998-02-10	Лекарственное средство для лечения заболеваний животных микробной этиологии, способ лечения желудочно-кишечных заболеваний животных микробной этиологии и способы лечения гинекологических заболеваний коров микробной этиологии
US3397268A (en)	1968-08-13	Process of treating herpes simplex with 1-beta-d-arabinofuranosylcytosine
RU2145499C1 (ru)	2000-02-20	Препарат для лечения и профилактики желудочно-кишечных и респираторных заболеваний новорожденных телят и ягнят - гастропульмин
HU198843B (en)	1989-12-28	Process for producing veterinary compositions with disinfecting and antiinflammatory action, comprising natural active ingredient and suitable particularly for treating mastitis
GB2108840A (en)	1983-05-25	Therapeutic use of imidazolidinyl urea
EP0080281A1 (en)	1983-06-01	Therapeutic use of allantoin-formaldehyde condensation products
Bello et al.	1985	Salmonella dublin neck abscess
Scheidy	1951	Recent advances in veterinary chemotherapy